3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
46
Neoplasms
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Cisplatin
15
pembrolizumab
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Carboplatin
10
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Paclitaxel
7
durvalumab
6
Radiotherapy, Intensity-Modulated
6
Cetuximab
6
cemiplimab
5
Radiotherapy
5
Radiation
5
Pemetrexed
5
Nivolumab
5
Biopsy
5
Ipilimumab
4
Fluorouracil
4
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
4
(225)Ac-DOTA-c(RGDyK)
4
poly ICLC
3
osimertinib
3
atezolizumab
3
Taxes
3
Oxaliplatin
3
Docetaxel
3
ipatasertib
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma
×
enzalutamide
×
90 days
×
Clear all
No trials found.